UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2024

BioXcel Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

001-38410 (Commission File Number)

Delaware (State or other jurisdiction of incorporation) 82-1386754 (IRS Employer Identification No.)

555 Long Wharf Drive New Haven, CT 06511

(Address of principal executive offices, including Zip Code)

(475) 238-6837

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	BTAI	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On April 22, 2024, BioXcel Therapeutics, Inc. (the "Company" or "BioXcel") issued an updated corporate presentation, including its clinical development programs and business strategy. A copy of the presentation is furnished hereto as Exhibit 99.1 and is incorporated herein by reference and will also be available through the "Investors & Media" page of the Company's website at http://www.bioxcellherapeutics.com.

The information in this Item 7.01 on this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On April 22, 2024, the Company provided the following updates regarding the planned design of its SERENITY At-Home Phase 3 trial (which refers to the Company's redesigned SERENITY III trial) to evaluate BXCL501, the Company's investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with bipolar disorders or schizophrenia in the home setting. The Company's plan to conduct this trial using a 120 mcg dose is based on feedback received from the U.S. Food and Drug Administration (FDA) following the recent receipt of minutes from the Type C meeting held with the agency on March 6, 2024.

SERENITY At-Home Pivotal Phase 3 Trial Design Summary

- The SERENITY At-Home Phase 3 trial is designed as a double blind, placebo-controlled study to evaluate the safety and efficacy of a 120 mcg dose of BXCL501 over a 12-week period.
- · The outpatient trial is expected to enroll a total of approximately 200 patients with agitation associated with bipolar disorder or schizophrenia.
- · Patients will self-administer 120 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.
- · The primary objective is safety with efficacy measures as exploratory endpoints to evaluate use in the outpatient setting.

In addition, the Company expects to enroll approximately 30 patients in a separate study to evaluate the correlation between patient-reported or informant-reported efficacy with trained rater-reported efficacy using Positive and Negative Syndrome Scale-Excitatory Component (PEC) measurements.

Forward-Looking Statements

This Current Report on Form 8-K ("Form 8-K") includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Form 8-K other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the planned trial design of the SERENITY At-Home Phase 3 trial; and the potential for the results from the Company's completed, ongoing and proposed clinical trials to support regulatory approach for its product candidates in both the care-facture of the Sections. When used herein, words including "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "predict," "should," "target, "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history and limited revenue generation; its incurrence of significant losses; its strategic reprioritization and related reduction in force may not achieve its intended outcome; its need for substantial additional funding and ability to raise capital when needed; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; risks related to the limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting; its dependence on the success and commercialization of IGALMI, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; interim "top-line" and preliminary data from its clinical trials may change and result in material changes in the final data; its ability to receive regulatory approval from the FDA and comparable foreign authorities for its product candidates; clinical trials are expensive, time-consuming, difficult to design, difficult to conduct, and involve an uncertain income; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company's product candidates may not be accepted by physicians or the medical community in general; the Company's estimated number of episodes of agitation and its corresponding estimated total addressable market are subject to inherent challenges and uncertainties; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies. its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company's product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; the Company is and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business, which could be costly and time-comming to defend and could result in unfavorable outcomes; risks related to unfavorable global political or economic events and conditions; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care "fraud and abuse" laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption "Risk Factors" in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at <u>www.sec.gov</u> and the Investors section of the Company's website at <u>www.bioxceltherapeutics.com</u>. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any such forward-looking statements represent management's estimates as of the date of this Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Ì	<i>′</i>	
	Exhibit No.	Description
	<u>99.1</u>	BioXcel Therapeutics, Inc. April 2024 Presentation
	104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 22, 2024

BIOXCEL THERAPEUTICS, INC.

/s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer



Al-Driven Transformative Medicines in Neuroscience

April 2024

cel Therapeutics | 555 Long Wharl Drive, 12th Floor | New Haven, CT 06511 | bioxceltherapeutics.com

NASDAQ: BTA

Forward-Looking Statements


This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation other than statements of historical fact should be considered forward-looking statements, including without limitation, statements related to the safety, efficacy, and regulatory and clinical design or progress, potential regulatory submissions, approvals and timing thereof for BXCL501 as a potential acute treatment for AAD or for agitation associated with bipolar disorders or schizophrenia in the at-home setting; developments and plans relating to the SERENITY and TRANQUILITY programs; and the potential for the results from the Company's completed, ongoing and proposed clinical trials to support regulatory indicident, "police," "stondul," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its evaluated in forward-looking attements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectation and beliefs, but they are inherently uncertain.

The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history and limited revenue generation; its incurrence of significant losses; its strategic reprioritization and related reduction in force may not achieve its intended outcome; its need for substantial additional funding and ability to raise capital when needed; its significant indebtedness, ability to comply with covenant obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; risks related to the limited clinical data supporting potential safety or efficacy of BXCL501 for use in the athome setting; its dependence on the success and commercialization of IGALMI, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; interim "top-line" and preliminary data from its clinical trials may change and result in material changes in the final data; its ability to receive regulatory approval from the FDA and comparable foreign authorities for its product candidates; clinical trials are expensive, time-consuming, difficult to design, difficult to conduct, and involve an uncertain income; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company's product candidates may not be accepted by physicinal studies to predic future clinical studies to predic future clinical studies; its ability to comply with the extensive and uncertainties; the Company site predice flexes caused by the Company's product candidates; its novel approach to the discovery and development of product candidates based on Evolutional studies to predic future clinical studies; the ability to any the future be subject to legal proceedin

INDUSTRY AND OTHER DATA

Unless otherwise indicated, information contained in this presentation concerning our industry and the markets in which BioXcel Therapeutics operates, including its general expectations, market position and market opportunity, is based on its management's estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. While BioXcel Therapeutics believes the information. Management's estimates are derived from publicity available information, their knowledge of the company's industry and their assumptions based on such information and BioXcel Therapeutics believes to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in BioXcel Therapeutics' fuer periodic reports filed with the SEC under the captions "Forward Looking Statements," "Risk Factor Summary" and "Risk Factors." These and other factors could cause BioXcel Therapeutics' fuer performance and market expectations to differ materially from its assumptions and estimates.





About BioXcel Therapeutics



Our Mission

Develop transformative medicines in neuroscience utilizing artificial intelligence

therapeutic

Strong Value Proposition and Long-Term Growth Potential


Transformative approach leveraging technology, clinical, and commercial expertise



 Data on file. BioXcel Therapeutics, Inc. New Haven, CT December 2020. 2, Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-1540. 3. National Institute of Mental Health. Prevalence of bipolar disorder in adults. November 2017. Accessed December 16, 2022. <u>https://www.nimh.nih.gov/health/statistics/bipolar-disorder</u>.
*Actual addressable market may be smaller



Corporate Growth Drivers to Advance Land and Expand Strategy



1. Data on file. BioXcel Therapeutics, Inc. New Haven, CT December 2020. 2. Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-1540. 3. National Institute of Mental Health. Prevalence of bipolar disorder in adults. November 2017. Accessed December 16, 2022. https://www.nimh.nih.gov/health/statistics/bipolar-disorder._*Actual addressable market may be smaller



Neuroscience Clinical Development

Compound	Indication/Proposed Indication	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Marketed
IGALMI™	Acute treatment of agitation associated with schizophrenia or bipolar I or II						
(dexmedetomidine) sublingual film	etomidine) disorder in adults under gual film healthcare provider supervision						
	TRANQUILITY PROGRAM Acute treatment of agitation associated with Alzheimer's dementia						
BXCL501	SERENITY PROGRAM Acute treatment of agitation associated with bipolar disorders/schizophrenia (at home)						
	Opioid Use Disorder (OUD)*						
	Post Traumatic Stress Disorder (PTSD)*			,			
BXCL502 (latrepirdine)	Chronic agitation in dementia						
Candidate BXCL503	Apathy in dementia						
Candidate BXCL504	Aggression in dementia						
	nvestigator-sponsored trials v of investigational agents and/or investigational uses of approv	ved products have not been e	established			b	bioxcel therapeutic

As of April 22, 2024

Leadership Expertise



Acute Treatment of Agitation Associated with Alzheimer's Dementia (AAD)

TRANQUILITY Program



AAD is Debilitating for Patients and a Burden for Caregivers

Agitation cited as a top driver in deciding to move a patient from home setting to residential care facility

- · Nearly 7 million Alzheimer's dementia patients in the U.S., with approximately 50% suffering from agitation.²
- AD-related agitation typically worsens over time²
 - Both the number and severity of agitation episodes increase²
 - Often places significant burden on caregivers^{1,2}
- No FDA-approved therapeutic options for an as-needed (PRN) acute treatment of agitation in Alzheimer's patients³
- 1. 2.
- Data on File InVibe Patient and Caregiver Research (n=75) December 2022 Alzheimer's Association. 2023 Alzheimer's Disease Facts and Figures. Accessed November 14, 2023. <u>https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf</u>. Halpern R, Seara J, et al. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia... Int J Geriatri Psychiatry. 2019; 34: 420-431. Joint Meeting of the Psychopharmacologic and the Peripheral and Central Nervous System Drugs Advisory Committee Meeting April 14th, 2023



TRANQUILITY Program Offers Potential Path to sNDA




- · Plan to discuss details of requirement for long-term safety data at future meeting with FDA**
- Company has developed preliminary TRANQUILITY At-Home trial design and is re-evaluating initiation timing

* Trial protocol under development, design may be subject to change. ** Per ICH guidelines, the Company may be required to collect 6-month safety data from at least 300 patients and 1-year safety data from at least 100 patients prior to submitting any sNDA




Evaluating BXCL501 for AAD in High to Low Care Settings

Clinical trial strategy designed to maximize potential commercial opportunity across patient locations



TRANQUILITY In-Care Study Design*




Feasibility cohort of 20 patients for at-home setting**

- · Design: Randomized, double-blind, placebo-controlled, parallel group trial
- Power: Over 80% power
- Inclusion Criteria
 - Patients with probable AD (mild, moderate, or severe, MMSE ≤ 25), who experience agitation, and residing in skilled nursing facilities, memory care units, or assisted living facilities
 - Patients with episodes of agitation in the month prior to enrollment
 - PEC total score ≥14 prior to randomization
- · Primary Endpoint: Change from baseline of PEC total score at 2 hours for first dose
- Study Duration: 12 weeks with assessment of continued efficacy (up to 3 PECs)

*For illustrative purposes only: protocol under development and trial design may be subject to change. The FDA has not provided feedback on this trial. ** Represents a separate cohort of 20 patients who reside at home in addition to the 150 patients who are in care facilities



Preliminary TRANQUILITY At-Home Study Design*



· Study Design: Randomized, double-blind, placebo-controlled, parallel group trial

- · Primary Objective: Safety and tolerability of BXCL501 60 mcg
- Inclusion Criteria
 - Patients with mild, moderate, or severe probable AD who experience agitation, MMSE ≤ 25
 - Patients with not more than three episodes of agitation per week in the month prior to enrollment
 - Patients with caregivers
- Treatment
 - BXCL501 60 mcg or placebo administered for agitation in at-home setting

* For illustrative purposes only. Protocol under development and trial design may be subject to change. The FDA has not provided feedback on this trial.



Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (at-home setting)

SERENITY Program



Agitation: Relatively Common and Difficult-to-Manage¹

Debilitating for Patients and Threatening for Healthcare Providers




1. Sacchetti E, Amore M, Di Sciascio G, et al. Psychomotor agitation in psychiatry: an Italian expert consensus. Evidence-based Psychiatry: Care. 2017;11:1-24. 2. Dundar Y, Greenhaigh J, Richardson M, et al. Pharmacological treatment of acute agitation associated with psychici and bipolar disorder: a systematic review and meta-analysis. Hum. Psychopharmacol. 2016;31(4):268-285. 3. Garriga M, Pacchiardti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):261-28. 4. Nordstrom K, Zan LS, Wilson MP, et al. Medical evaluation and triage of the agitated patient: consumus statement of the American associated of the American associated of the American association for emergency psychiatry project Beta molicial evaluation workgroup. West J Emerg Med. 2017;17(3):161. 5. Matritoz-Raga Jamore M. Di Sciascio G, et al. 13 international acyter associated of the American associated by phase of agitation in psychiatry. Start Experission and Bipolar Gibsoriter: a systematic review and negative synchrone sciel (SIG) (SIG)




SERENITY Program Seeks Potential IGALMI™ Label Expansion

Potential opportunity for at-home use in treating agitation associated with bipolar disorders or schizophrenia



Planned SERENITY At-Home Study Design




Recruitment Criteria

- Patients alone or with informants with at least 1 treated episode of agitation
- Patients with episodes of agitation in the month prior to enrollment
- Treatment
 - Single dose to treat agitation at levels that typically require intervention
 - Maximum of 1 dose of study medication within 12 hours



Potential for Bipolar Disorder/Schizophrenia Patient Use of BXCL501 At Home

When shown product profile stimulus, patients said they would use a product with the BXCL501 target profile for 80% of their bipolar/schizophrenia agitation episodes, and for those on therapy it could be adjunctive



IGALMI[™] Commercialization

Following commercial field workforce reduction in August 2023



IGALMI[™] (dexmedetomidine) Sublingual Film

Approved for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under healthcare provider supervision



IGALMI[™] Indication and Important Safety Information

IGALMI™ (dexmedetomidine) sublingual film is a prescription medicine, administer under the supervision of a health care provider, that is placed under the torgue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipclar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known i IGALMI is safe and effective in children.

IMPORTANT SAFETY INFORMATION IGALMI can cause serious side effects,

Decreased blood pressure, low blood pressure upon standing, and slown normal heart rate, which may be more likely in patients with low blood volume diabetes, chronic high blood pressure, and doler patients. IGALM is taken un supervision of a healthcare provider who will monitor vital signs (like blood pre and heart rate) and alertness ster IGALMI is administered to help prevent fail fainting. Patients should be adequately hydrated and sit or lie down after takin IGALM and instructed to tell their healthcare provider if they feel dizzy, lighthe or faint.

 Heart thythm changes (OT interval prolongation). (GALM should not be gip patients with an abnormal heart thythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or laking other drugs that could affect heart rhythm. Taking IGALM with a history of abnormal heart rhythm can incre the risk of loxades de pointes and sudden death. Patients should be instructed.

Sleepiness/drowsiness. Patients should not perform activities requiring men alertness, such as driving or operating hazardous machinery, for at least 8 ho offer tarties ICAL MI

Withdrawal reactions, tolerance, and decreased response/efficacy. IGAL9 not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased respo IGALMI may occur if IGALMI is used longer than 24 hours.

The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, mouth, low blood pressure, and low blood pressure upon standing.

hese are not all the possible side effects of IGALMI. Patients should speak with t ealthcare provider for medical advice about side effects.

Patients should tell their healthcare provider about their medical history, incluthey suffer from any known heart problems, low potassium, low magnesium, low bi pressure, low heart rate, diabetes, high blood pressure, history of fainling, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart i or take anesthetics, sedalives, hypnotics, and oploids.


Everyone is encouraged to report negative side effects or prescription drugs to the visit www.fda.gov/medwatch or call 1-900-PLA-1088, You can also contact BioXee Therapeutics, Inc. at 1-833-201-1068 or <u>medinfo@bioxceltherapeutics.com</u>. Please see full <u>Prescribing Information</u>.

Market Conditions Favorable for Continued Demand Growth


J-Code issuance, P&T formulary wins, and volume contracting to drive commercial progress following commercial field workforce reduction

- Targeting/engaged with key hospital systems for volume-based contracting
- J-Code granted by CMS effective Jan. 1, 2024 (streamlines and standardizes reimbursement)
- Over 250 hospital P&T approvals to date, with large volume in Q4 2023
- First large academic center approval in Q4 2023
- Activating new channels such as Dept. of Veterans Affairs and Dept. of Corrections

Source: Data on File, 2023



Agitation Franchise Expansion Plan




Al-Driven Drug Re-innovation Platform




AI Strategy to Accelerate Drug Re-Innovation Process

From product concept to first-in-human clinical trials using composite AI





NovareAI: Ecosystem for Drug Discovery and Development



Behavioral and Psychological Symptoms in Alzheimer's Disease


Identifying targets and compounds designed to address unmet medical needs in dementia





BXCL502 Presents a Compelling Value Proposition

Formulation studies are ongoing



Latrepirdine (Dimebon): Clinical Safety Data, Preclinical Confidence in Rationale, and Early Sign of Potential Efficacy

Data support development for treatment of neuropsychiatric symptoms associated with dementia



- Over 1000 patients with AD exposed for 26 weeks and 500 up to 52 weeks (*Trials conducted by Pfizer and Medivation*)
- Showed activity in 5 preclinical models of neuropsychiatric symptoms (*Trials conducted by BioXcel Therapeutics*)
- Secondary efficacy endpoints measuring changes in Neuropsychiatric Inventory (NPI), showed numerical superiority over placebo in 3 trials. NPI measures frequency and severity of several neuropsychiatric symptoms.

(Trials conducted by Pfizer and Medivation)

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established



Recent Examples of Successful CNS Drug Re-Innovation

DRUG/COMPANY	CHALLENGE	SOLUTION	STATUS	
Dextromethorphan Axsome Therapeutics	Low bioavailability & metabolites that may cause side effects	Bupropion significantly increases dextromethorphan bioavailability	Successful clinical trial/depression	
Xanomeline Karuna Therapeutics	Peripheral side effects Block peripheral effects with trospium		Successful clinical trial/schizophrenia	
Dexmedetomidine IGALMI™ BioXcel Therapeutics	Poor oral bioavailability (<20%)	Use sublingual film to increase bioavailability (sublingual bioavailability ~70%)	Approved to treat adults with agitation associated with schizophrenia or bipolar I or II disorder	


Latrepirdine + "Metabolic Stabilizer" = BXCL502

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established




Immuno-Oncology

OnkosXcel Therapeutics A subsidiary of BioKet Therapeutics. Inc



BXCL701: Strong Value Proposition in Hard-to-Treat Tumors



2. <u>Company anouncement</u>, February 12, 2024: FDA designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability.



Immuno-Oncology Clinical Development

Compound	Proposed Indication	Preclinical	Phase 1	Phase 2	Phase 3	Expected Upcoming Milestone	Collaborator
BXCL701 Company-	Small Cell Neuroendocrine Prostate Cancer (SCNC)					FDA Meeting	13 centers US / UK
sponsored trials	Small Cell Lung Cancer (SCLC)					Initiate Phase 1b/2	
BXCL701 Investigator- sponsored	Metastatic Pancreatic Ductal Adenocarcinoma					Phase 2 readout	Georgetown Lombardi Comprehensive Cancer Center Supply agreement: Merck & Co.
trials	Acute Myeloid Leukemia (AML)					Phase 1b readout	Dana-Farber Cancer Institute
BXCL702 BXCL701 follow-on/ novel DPP inhibitor	Solid Tumors					Candidate nomination	
As of April 22, 2024							

The safety and efficacy of these investigational agents have not been established.

therapeutic

Thank you!

